Pfizer Ltd
NSE:PFIZER

Watchlist Manager
Pfizer Ltd Logo
Pfizer Ltd
NSE:PFIZER
Watchlist
Price: 5 025.2 INR 0.92% Market Closed
Market Cap: 229.9B INR

Pfizer Ltd
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Pfizer Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Pfizer Ltd
NSE:PFIZER
Income from Continuing Operations
₹8.4B
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
14%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Income from Continuing Operations
₹57.4B
CAGR 3-Years
23%
CAGR 5-Years
22%
CAGR 10-Years
15%
Cipla Ltd
NSE:CIPLA
Income from Continuing Operations
₹54.5B
CAGR 3-Years
27%
CAGR 5-Years
24%
CAGR 10-Years
12%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Income from Continuing Operations
₹104.2B
CAGR 3-Years
35%
CAGR 5-Years
59%
CAGR 10-Years
10%
Lupin Ltd
NSE:LUPIN
Income from Continuing Operations
₹43.5B
CAGR 3-Years
271%
CAGR 5-Years
N/A
CAGR 10-Years
7%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Income from Continuing Operations
₹21.4B
CAGR 3-Years
39%
CAGR 5-Years
13%
CAGR 10-Years
4%
No Stocks Found

Pfizer Ltd
Glance View

Pfizer Ltd., a giant in the pharmaceutical industry, has woven its identity deeply into the fabric of healthcare innovation. Established initially to create chemical compounds, it evolved into a pharmaceutical pioneer through a series of strategic developments and acquisitions. Headquartered in New York, the company has a sprawling international presence, with an intricate network of research facilities, manufacturing plants, and marketing offices spread across the globe. This global footprint empowers Pfizer to leverage diverse talent and resources, driving innovation and efficiency. At the core of Pfizer’s operations is its research and development engine, a crucial element that churns out new medicines and therapies. By investing heavily in R&D, absorbing over $8 billion annually, the company relentlessly pursues breakthroughs in areas such as oncology, vaccines, rare diseases, and primary care, consistently bringing advanced treatments from laboratories to clinics. The way Pfizer sustains its financial health is as much about strategic foresight as it is about scientific prowess. Its revenue streams are crafted through a mix of patent-protected pharmaceuticals, consumer health products, and vaccines. The blockbuster drug era, epitomized by the success of Lipitor, showcased its capability to capture market leadership efficiently. More recently, Pfizer's collaboration with BioNTech on the COVID-19 vaccine highlighted its agility and strategic partnerships. Such initiatives solidify its position in the market and open lucrative opportunities. Beyond products, Pfizer employs a robust marketing strategy and leverages an extensive distribution network to ensure these innovations reach a global clientele efficiently. Through a combination of smart financial management, cutting-edge research, and decisive partnerships, Pfizer Ltd. has positioned itself as a towering figure in the pharmaceutical landscape, capable of responding to global health challenges while ensuring sustainable growth.

PFIZER Intrinsic Value
3 342.33 INR
Overvaluation 33%
Intrinsic Value
Price

See Also

What is Pfizer Ltd's Income from Continuing Operations?
Income from Continuing Operations
8.4B INR

Based on the financial report for Sep 30, 2025, Pfizer Ltd's Income from Continuing Operations amounts to 8.4B INR.

What is Pfizer Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
14%

Over the last year, the Income from Continuing Operations growth was 36%. The average annual Income from Continuing Operations growth rates for Pfizer Ltd have been 11% over the past three years , 11% over the past five years , and 14% over the past ten years .

Back to Top